These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34306269)

  • 1. Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data.
    Niu X; Dennen S; Dembek C; Laubmeier K; Liu Y; Veeranki P; Tocco M; Williams GR
    Curr Ther Res Clin Exp; 2021; 94():100629. PubMed ID: 34306269
    [No Abstract]   [Full Text] [Related]  

  • 2. Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: a retrospective analysis of Medicaid claims data.
    Niu X; Veeranki P; Dennen S; Dembek C; Laubmeier K; Liu Y; Williams GR; Loebel A
    Curr Med Res Opin; 2021 May; 37(5):839-846. PubMed ID: 33682547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study.
    Kadakia A; Dembek C; Liu Y; Dieyi C; Williams GR
    J Med Econ; 2021; 24(1):1212-1220. PubMed ID: 34647502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.
    Ng-Mak D; Halpern R; Rajagopalan K; Loebel A
    Curr Med Res Opin; 2019 Feb; 35(2):211-219. PubMed ID: 29625538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
    Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
    Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.
    Bergeson JG; Kalsekar I; Jing Y; You M; Forbes RA; Hebden T
    Am Health Drug Benefits; 2012 Sep; 5(6):379-86. PubMed ID: 24991334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
    Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
    J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder.
    Yan T; Greene M; Chang E; Houle CR; Tarbox MH; Broder MS
    Clinicoecon Outcomes Res; 2020; 12():81-89. PubMed ID: 32104020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
    Kim E; You M; Pikalov A; Van-Tran Q; Jing Y
    BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
    Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
    Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.
    Kadakia A; Dembek C; Heller V; Singh R; Uyei J; Hagi K; Nosaka T; Loebel A
    BMC Psychiatry; 2021 May; 21(1):249. PubMed ID: 33975574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
    Tohen M; Ng-Mak D; Rajagopalan K; Halpern R; Chuang CC; Loebel A
    Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28590601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality risk and mood stabilizers in bipolar disorder: a propensity-score-weighted population-based cohort study in 2002-2018.
    Chan JKN; Wong CSM; Fang CZ; Hung SC; Lo HKY; Chang WC
    Epidemiol Psychiatr Sci; 2024 May; 33():e31. PubMed ID: 38779809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.
    Halpern R; Nadkarni A; Kalsekar I; Nguyen H; Song R; Baker RA; Nelson JC
    Ann Pharmacother; 2013; 47(7-8):933-45. PubMed ID: 23715066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing levels of antipsychotics and mood stabilizers in bipolar disorder: A Nationwide cohort study on relapse risk and treatment safety.
    Lintunen J; Hamina A; Lähteenvuo M; Paljärvi T; Tanskanen A; Tiihonen J; Taipale H
    Acta Psychiatr Scand; 2025 Jan; 151(1):81-91. PubMed ID: 39355920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.